The purpose of this study is to look at combining the study drug IMGN632 with standard therapies (azacitidine and/or venetoclax) for acute myeloid leukemia (AML). The study will look at what effects (both good and/or bad) this combination has on the cancer, how well this combination works to treat cancer, and what a safe dose of the study drug is.

IMGN5632 is considered experimental, meaning it has not yet been approved by the U.S. Food and Drug Administration (FDA) or other health authorities.

Participants will receive IMGN5632 in combination with venetoclax andazacitidine.

The purpose of this clinical research study to find out if the experimental drug, IDE397, is safe and helpful in those who have any type of cancer that is considered a “solid tumor” (not a blood cancer) that is caused by an error in the tumor DNA associated with the gene, methylthioadenosine phosphorylase (MTAP). The loss of the MTAP gene is an error seen in many different types of cancers. Participants must have loss of the MTAP gene in order to participate in the study.
   

This is a clinical trial for adults who have been diagnosed with relapsed or refractory multiple myeloma.
   

The purpose of the study is to see if short course radiation treatment to the tumor combined with two investigational drugs AB928 and AB122 will help in eliminating the tumor and thereby increase response to the treatment in patients with rectal cancer.
   

This is a randomized study comparing 5 radiation therapy treatments to 2 radiation therapy treatments with MRI guidance in patients with prostate cancer. The study will assess the potential benefit of limiting radiation doses received by normal tissues, namely the bladder and the rectum, with advanced MRI image guidance and to compare urinary and bowel side effects between the two treatment options.  Prostate cancer cure and control and quality of life will also be examined. 

Learn more about the trial details in this informational video:

This is a trial for adults who have a diagnosis of a malignant (cancerous) brain tumor and have either been newly diagnosed with glioblastoma and completed standard chemotherapy and radiation or have a recurrence of glioblastoma (the tumor has come back).   

The purpose of this study is to evaluate the safety of an investigational drug, “INCB000928” alone and in combination with ruxolitinib (Jakafi), and to find out what effects, if any, the drug or investigational combination has on people with anemia due to myeloproliferative disorders.

This is an open-label study, which means that both you and your study doctor will know whether you are receiving study drug alone or the investigational combination.

Treatment for Primary Mediastinal (Thymic) Large B-Cell Lymphoma (PMBCL) involves chemotherapy combined with an immunotherapy called rituximab. This combination is also known as the chemo-immunotherapy backbone. There are two types of chemo-immunotherapy backbone treatments for PMBCL: either R-CHOP or DA-EPOCH-R.
   
These drugs effectively treat PMBCL, but are known to cause long-term side effects at high doses. Side effects are unintended and unwanted results of treatment. Study doctors are interested in finding an effective treatment that improves the outcome of PMBCL.
   

Treatment for acute myeloid leukemia (AML) involves high doses of a common class of chemotherapy drugs called anthracyclines. One anthracycline drug which is effective in treating AML is daunorubicin, but high doses are known to cause long-term side effects, especially to the heart. (Side effects are unintended and unwanted results of treatment.) Study doctors are interested in finding an effective treatment for AML patients that reduces the potential for long-term side effects.
   

This clinical trial is for men or women who have inadequately controlled Type 2 diabetes and are currently on stable doses of basal insulin. The purpose of this study is to learn more about the use of the Fractyl Revita System for the treatment of Type 2 diabetes for individuals who are on insulin therapy.
     
The study device, the Revita System, has not been approved for use by the Food and Drug Administration (FDA) in the United States since the device is experimental. The Revita System is commercially available in the United Kingdom.